Orphan Drug Exemptions May Not Be Warranted, Analysis Finds
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The One Big Beautiful Bill Act includes a controversial provision exempting more orphan drugs from Medicare pricing negotiations, intended to encourage drug development for rare diseases.
- A new analysis finds the broadened exemption may not be warranted, directly challenging the development-incentive rationale.
- The Inflation Reduction Act provision, in effect for three years, allows Medicare to negotiate prices for certain drugs but originally exempted orphan drugs with only one orphan designation and FDA approval.
- The Orphan Cures Act, part of the Big Beautiful Bill Act that became law last year, expanded the exemption to include medicines with multiple orphan indications.
- The law also delayed the timelines for when an otherwise eligible orphan drug may be considered for price negotiations.
Why it matters: The analysis challenges the development-incentive rationale behind the Orphan Cures Act's expanded orphan drug exemption, which excludes medicines with multiple orphan indications from Medicare price negotiations and pushes back timelines for other eligible orphan drugs.
